DK0695758T3 - Pentapeptidamider og -estere til inhibering af human cancer - Google Patents

Pentapeptidamider og -estere til inhibering af human cancer

Info

Publication number
DK0695758T3
DK0695758T3 DK95305129T DK95305129T DK0695758T3 DK 0695758 T3 DK0695758 T3 DK 0695758T3 DK 95305129 T DK95305129 T DK 95305129T DK 95305129 T DK95305129 T DK 95305129T DK 0695758 T3 DK0695758 T3 DK 0695758T3
Authority
DK
Denmark
Prior art keywords
esters
pentapeptidamides
human cancer
cancer inhibition
chem
Prior art date
Application number
DK95305129T
Other languages
Danish (da)
English (en)
Inventor
George R Pettit
Jayaram K Srirangam
Original Assignee
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arizona filed Critical Univ Arizona
Application granted granted Critical
Publication of DK0695758T3 publication Critical patent/DK0695758T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK95305129T 1994-08-01 1995-07-21 Pentapeptidamider og -estere til inhibering af human cancer DK0695758T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/283,806 US5521284A (en) 1994-08-01 1994-08-01 Human cancer inhibitory pentapeptide amides and esters

Publications (1)

Publication Number Publication Date
DK0695758T3 true DK0695758T3 (da) 2002-08-19

Family

ID=23087626

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95305129T DK0695758T3 (da) 1994-08-01 1995-07-21 Pentapeptidamider og -estere til inhibering af human cancer

Country Status (9)

Country Link
US (1) US5521284A (de)
EP (1) EP0695758B1 (de)
JP (1) JP3579751B2 (de)
AT (1) ATE217883T1 (de)
CA (1) CA2154206A1 (de)
DE (1) DE69526756T2 (de)
DK (1) DK0695758T3 (de)
ES (1) ES2176285T3 (de)
PT (1) PT695758E (de)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2282504A1 (en) 1997-02-25 1998-08-27 Jun-Ping Xu Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18
EP1229934B1 (de) 1999-10-01 2014-03-05 Immunogen, Inc. Zusammensetzungen und verfahren zur behandlung von krebs mittels immunkonjugaten und chemotherapeutischen agenzien
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
EP1545613B9 (de) * 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin-konjugate und ihre verwendung zur behandlung von krebs, einer autoimmunkranheit oder einer infektionskrankheit
ATE472338T1 (de) 2003-02-20 2010-07-15 Seattle Genetics Inc Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
CN107213469A (zh) * 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
DE602005022928D1 (de) 2004-11-30 2010-09-23 Abgenix Inc Antikörper gegen gpnmb und ihre verwendungen
EP2511299A1 (de) 2005-04-19 2012-10-17 Seattle Genetics, Inc. Humanisierte, anti-CD70-bindende Wirkstoffe und ihre Verwendung
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
WO2007011968A2 (en) 2005-07-18 2007-01-25 Seattle Genetics, Inc. Beta-glucuronide-linker drug conjugates
KR101506466B1 (ko) 2006-05-16 2015-03-27 파마사이언스 인크. Ｉａｐ ｂｉｒ 도메인 결합 화합물
US7910108B2 (en) * 2006-06-05 2011-03-22 Incyte Corporation Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
WO2008070593A2 (en) 2006-12-01 2008-06-12 Seattle Genetics, Inc. Variant target binding agents and uses thereof
AU2008276128B2 (en) 2007-07-16 2013-10-10 Genentech, Inc. Humanized anti-CD79b antibodies and immunoconjugates and methods of use
ES2381788T3 (es) 2007-07-16 2012-05-31 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
ES2908934T3 (es) 2007-10-04 2022-05-04 Zymogenetics Inc ZB7H6 miembro de la familia B7 y composiciones y métodos relacionados
EP3115469B1 (de) 2007-11-19 2020-04-29 Celera Corporation Lungenkrebsmarker und verwendungen davon
BRPI0907046A2 (pt) 2008-01-18 2015-07-28 Medimmune Llc Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo
IL287292B (en) 2008-01-31 2022-09-01 Genentech Inc and fusion antibody-drug-cd79b engineered antibodies cysteine-
CA2723197C (en) 2008-05-02 2017-09-19 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
MX2012000121A (es) 2009-06-22 2012-03-07 Medimmune Llc Regiones fc modificadas para la conjugacion especifica del sitio.
NZ623607A (en) 2009-10-23 2016-07-29 Millennium Pharm Inc Anti-gcc antibody molecules and related compositions and methods
MX2012006443A (es) 2009-12-09 2012-06-28 Inst Nat Sante Rech Med Anticuerpos monoclonales que se enlazan a b7h6 y usos de los mismos.
EP3395361A1 (de) 2010-02-08 2018-10-31 Agensys, Inc. An 161p2f10b-proteine bindende antikörper-wirkstoffkonjugate (adc)
RU2567544C2 (ru) 2010-02-12 2015-11-10 Фармасайенс Инк. Bir домен iap связывающие соединения
EP2552965A2 (de) 2010-03-31 2013-02-06 Boehringer Ingelheim International GmbH Anti-cd4-antikörper
EA201790850A1 (ru) 2010-09-29 2017-11-30 Эдженсис, Инк. Конъюгаты антитело-лекарственное средство (adc), связывающиеся с белками 191p4d12
CN106563128B (zh) 2010-10-22 2020-05-22 西雅图遗传学公司 以奥里斯他汀为主的抗体药物结合物和结合mTOR的抑制剂在制备治疗癌症药物中的用途
CN103732257A (zh) 2011-05-16 2014-04-16 皇家飞利浦有限公司 生物正交药物活化
JP2014516960A (ja) 2011-05-19 2014-07-17 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） 抗ヒトｈｅｒ３抗体及びその使用
TWI597065B (zh) 2011-06-10 2017-09-01 梅爾莎納醫療公司 蛋白質－聚合物－藥物共軛體
CA2839480A1 (en) 2011-06-22 2012-12-27 Inserm (Institut National De La Sante Et De La Recherche Medicale) Anti-axl antibodies and uses thereof
WO2012175691A1 (en) 2011-06-22 2012-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-axl antibodies and uses thereof
MY168297A (en) 2011-11-17 2018-10-23 Pfizer Cytotoxic Peptides and Antibody Drug Conjugates Thereof
ES2721882T3 (es) 2011-12-23 2019-08-06 Pfizer Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
CA2862292C (en) 2012-01-20 2019-10-08 Sea Lane Biotechnologies, Llc Binding molecule conjugates
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
WO2013174783A1 (en) 2012-05-23 2013-11-28 Pieris Ag Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
JP6498600B2 (ja) 2012-06-08 2019-04-10 ストロ バイオファーマ インコーポレーテッド 部位特異的な非天然アミノ酸残基を含む抗体、その調製方法、及びその使用方法
SG11201408494UA (en) 2012-06-19 2015-02-27 Ambrx Inc Anti-cd70 antibody drug conjugates
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
KR102355959B1 (ko) 2012-08-23 2022-01-27 어젠시스 인코포레이티드 158p1d7 단백질에 결합하는 항체 약물 컨쥬게이트(ａｄｃ)
EP4074728A1 (de) 2012-08-31 2022-10-19 Sutro Biopharma, Inc. Modifizierte peptide mit einer azidogruppe
WO2014072897A1 (en) 2012-11-07 2014-05-15 Pfizer Inc. Anti-notch3 antibodies and antibody-drug conjugates
WO2014081303A1 (en) 2012-11-22 2014-05-30 Tagworks Pharmaceuticals B.V. Chemically cleavable group
EP2922818B1 (de) 2012-11-24 2018-09-05 Hangzhou Dac Biotech Co., Ltd Hydrophile binder und deren verwendung zur konjugation von wirkstoffen an zellbindende moleküle
AU2013359506B2 (en) 2012-12-10 2018-05-24 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
EP2931316B1 (de) 2012-12-12 2019-02-20 Mersana Therapeutics, Inc. Hydroxylpolymer-heilmittelproteinkonjugate
KR20150132864A (ko) 2013-03-15 2015-11-26 애브비 인코포레이티드 항체 약물 접합체(adc) 정제
KR102305226B1 (ko) 2013-03-15 2021-09-29 아비에 도이치란트 게엠베하 운트 콤파니 카게 항-egfr 항체 약물 접합체 제형
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
TWI646108B (zh) 2013-08-01 2019-01-01 艾澤西公司 結合至ｃｄ３７蛋白質之抗體藥物結合物（ａｄｃ）
KR20160055253A (ko) 2013-09-12 2016-05-17 할로자임, 아이엔씨 변형된 항-상피세포 성장인자 수용체 항체 및 이의 사용 방법
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
EP3054991B1 (de) 2013-10-11 2019-04-03 Mersana Therapeutics, Inc. Protein-polymer-wirkstoffkonjugate
CN115068626A (zh) 2013-10-11 2022-09-20 阿萨纳生物科技有限责任公司 蛋白-聚合物-药物缀合物
WO2015054691A2 (en) 2013-10-11 2015-04-16 The United States Of America, As Pepresented By The Secretary, Department Of Health And Human Services Tem8 antibodies and their use
US9644037B2 (en) 2013-10-18 2017-05-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that specifically bind ataxia telangiectasia-mutated and RAD3-related kinase phosphorylated at position 1989 and their use
EP3066118B1 (de) 2013-11-06 2020-01-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Alk-antikörper, konjugate und chimäre antigenrezeptoren und deren verwendung
EP3066124B1 (de) 2013-11-07 2021-01-06 INSERM - Institut National de la Santé et de la Recherche Médicale Gegen her3, neuregulin allosterische antikörpern
WO2015103549A1 (en) 2014-01-03 2015-07-09 The United States Of America, As Represented By The Secretary Department Of Health And Human Services Neutralizing antibodies to hiv-1 env and their use
EP3094350B1 (de) 2014-01-15 2020-03-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Auf knorpel gerichtete wirkstoffe und deren verwendung
DK3122757T3 (da) 2014-02-28 2023-10-09 Hangzhou Dac Biotech Co Ltd Ladede linkere og anvendelse deraf til konjugering
AR099812A1 (es) 2014-03-21 2016-08-17 Abbvie Inc Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
FR3020063A1 (fr) 2014-04-16 2015-10-23 Gamamabs Pharma Anticorps humain anti-her4
RU2747989C2 (ru) 2014-05-28 2021-05-18 Эдженсис, Инк. Производные пептидов долапроин-долаизолейина
US10934360B2 (en) 2014-07-31 2021-03-02 The Hong Kong University Of Science And Technology Human monoclonal antibodies against EPHA4 and their use
RS60349B8 (sr) 2014-09-23 2022-10-31 Hoffmann La Roche Postupak upotrebe anti-cd79b imunokonjugata
WO2016130969A1 (en) 2015-02-13 2016-08-18 George Robert Pettit Silstatin compounds
KR20170140180A (ko) 2015-02-24 2017-12-20 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도
MX2017011380A (es) 2015-03-09 2018-04-26 Agensys Inc Conjugados anticuerpo-farmaco (adc) que se ligan a proteinas flt3.
EP3091033A1 (de) 2015-05-06 2016-11-09 Gamamabs Pharma Anti-human-her3-antikörper und verwendungen davon
EP3295171A1 (de) 2015-05-12 2018-03-21 INSERM - Institut National de la Santé et de la Recherche Médicale Verfahren und kits zur markierung, zum nachweis und zur isolierung von foxp3+-regulierenden t-zellen, isolierten populationen von foxp3+-regulierenden t-zellen und verwendungen davon
US10526415B2 (en) 2015-05-22 2020-01-07 INSERM (Institut National de la Santé et de la Recherche Médicale) Human monoclonal antibodies fragments inhibiting both the Cath-D catalytic activity and its binding to the LRP1 receptor
EP3303391A1 (de) 2015-05-26 2018-04-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und pharmazeutische zusammensetzungen (ntsr1-inhibitoren) zur behandlung von hepatozellulären karzinomen
WO2016189118A1 (en) 2015-05-28 2016-12-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of prognosis and treatment of patients suffering from acute myeloid leukemia
AU2016277121C1 (en) 2015-06-12 2022-07-14 Lentigen Technology, Inc. Method to treat cancer with engineered T-cells
CA2991973C (en) 2015-07-12 2021-12-07 Suzhou M-Conj Biotech Co., Ltd. Bridge linkers for conjugation of a cell-binding molecule
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CA2997809A1 (en) 2015-10-07 2017-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
JP6821688B2 (ja) 2015-10-09 2021-01-27 ミルテニー・バイオテク・テクノロジー・インコーポレイテッドＭｉｌｔｅｎｙｉ Ｂｉｏｔｅｃ Ｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． キメラ抗原受容体および使用方法
US10556953B2 (en) 2015-10-12 2020-02-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Agent capable of depleting CD8 T cells for the treatment of myocardial infarction or acute myocardial infarction
CA3011455A1 (en) 2016-01-27 2017-08-03 Sutro Biopharma, Inc. Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
US11191821B2 (en) 2016-02-27 2021-12-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Peptide vaccine formulations and use thereof for inducing an immune response
EP3423112A4 (de) 2016-02-29 2020-02-26 Madrigal Pharmaceuticals, Inc. Hsp9-inhibitor-wirkstoff-konjugate
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
CA3017527A1 (en) 2016-03-25 2017-09-28 Seattle Genetics, Inc. Process for the preparation of pegylated drug-linkers and intermediates thereof
MX2018015272A (es) 2016-06-08 2019-08-12 Abbvie Inc Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
AU2017277914A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-CD98 antibodies and antibody drug conjugates
US20200338209A1 (en) 2016-06-08 2020-10-29 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
AU2017279550A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
CN109563167A (zh) 2016-06-08 2019-04-02 艾伯维公司 抗b7-h3抗体和抗体药物偶联物
US11617799B2 (en) 2016-06-27 2023-04-04 Tagworks Pharmaceuticals B.V. Cleavable tetrazine used in bio-orthogonal drug activation
EP4282969A3 (de) 2016-09-02 2024-01-31 Lentigen Technology, Inc. Zusammensetzungen und verfahren zur behandlung von krebs mit duocars
CA3042442C (en) 2016-11-14 2024-01-02 Hangzhou Dac Biotech Co., Ltd Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses of such conjugates with the linkers
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
WO2018129524A1 (en) 2017-01-09 2018-07-12 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-mesothelin immunotherapy
JP2020512312A (ja) 2017-03-24 2020-04-23 シアトル ジェネティックス， インコーポレイテッド グルクロニド薬物−リンカーの調製のためのプロセスおよびその中間体
AU2018240556A1 (en) 2017-03-24 2019-10-10 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD33 immunotherapy
EP3612567A4 (de) 2017-04-19 2020-11-11 Bluefin Biomedicine, Inc. Anti-vtcn1-antikörper und antikörper-wirkstoff-konjugate
CN111315414A (zh) 2017-06-22 2020-06-19 梅尔莎纳医疗公司 产生载药聚合物支架和蛋白-聚合物-药物缀合物的方法
US20200207859A1 (en) 2017-07-26 2020-07-02 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
US10442867B2 (en) 2017-07-31 2019-10-15 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
US10501539B2 (en) 2017-09-15 2019-12-10 Lentigen Technology Inc. Compositions and methods for treating cancer with anti-CD19 immunotherapy
MA50265A (fr) 2017-09-18 2020-07-29 Sutro Biopharma Inc Conjugués anticorps-récepteur alpha anti-folate et leurs utilisations
CA3078962A1 (en) 2017-10-16 2019-04-25 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd22 immunotherapy
WO2019094709A1 (en) 2017-11-09 2019-05-16 Pettit George R Betulastatin compounds
US10894819B2 (en) 2017-12-20 2021-01-19 Lentigen Technology, Inc. Compositions and methods for treating HIV/AIDS with immunotherapy
CA3099421A1 (en) 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B.V. Compounds comprising a linker for increasing transcyclooctene stability
WO2019212356A1 (en) 2018-05-04 2019-11-07 Tagworks Pharmaceuticals B .V. Tetrazines for high click conjugation yield in vivo and high click release yield
EP3813950A1 (de) 2018-06-29 2021-05-05 Boehringer Ingelheim International GmbH Anti-cd40-antikörper zur verwendung bei der behandlung von autoimmunerkrankungen
EP3820909B1 (de) 2018-07-11 2023-03-01 The United States of America, as represented by the Secretary, Department of Health and Human Services Monoklonaler antikörper zum nachweis des antiviralen arzneimittels emtricitabin (ftc, 2',3'-dideoxy-5-fluoro-3'-thiacytidin)
WO2020060944A1 (en) 2018-09-17 2020-03-26 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
CA3113058A1 (en) 2018-09-20 2020-03-26 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd123 immunotherapy
JP2022502043A (ja) 2018-09-26 2022-01-11 レンティジェン・テクノロジー・インコーポレイテッドLentigen Technology, Inc. 抗ｃｄ１９／ｃｄ２２免疫療法によりがんを処置するための組成物および方法
US20230021500A1 (en) 2018-10-29 2023-01-26 Mersana Therapeutics, Inc. Cysteine engineered antibody-drug conjugates with peptide-containing linkers
CN113412119A (zh) 2018-11-30 2021-09-17 莱蒂恩技术公司 用于用抗cd38免疫治疗来治疗癌症的组合物和方法
US20220064332A1 (en) 2018-12-19 2022-03-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treating cancers by immuno-modulation using antibodies against cathespin-d
US11969443B2 (en) 2019-03-06 2024-04-30 Lentigen Technology, Inc. Compositions and methods for treating cancer with self-driving chimeric antigen receptors
EP3962951A1 (de) 2019-05-03 2022-03-09 Sutro Biopharma, Inc. Anti-bcma-antikörper-konjugate
CN114364801B (zh) 2019-05-30 2024-04-19 莱蒂恩技术公司 用于用抗bcma免疫治疗来治疗癌症的组合物和方法
IL289094A (en) 2019-06-17 2022-02-01 Tagworks Pharmaceuticals B V Tetrazines for increasing the speed and yield of the "click release" reaction
AU2020297253B2 (en) 2019-06-17 2024-05-23 Tagworks Pharmaceuticals B.V. Compounds for fast and efficient click release
CA3142833A1 (en) 2019-07-02 2021-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind egfrviii and their use
EP3812008A1 (de) 2019-10-23 2021-04-28 Gamamabs Pharma Amh-kompetitiver antagonistischer antikörper
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
US20230095053A1 (en) 2020-03-03 2023-03-30 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
US11497770B2 (en) 2020-06-22 2022-11-15 Lentigen Technology, Inc. Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy
EP4213939A1 (de) 2020-09-21 2023-07-26 Boehringer Ingelheim International GmbH Verwendung von anti-cd40-antikörpern zur behandlung von entzündlichen erkrankungen
CA3171093A1 (en) 2020-11-05 2022-05-12 Dina SCHNEIDER Compositions and methods for treating cancer with anti-cd19/cd22 immunotherapy
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
AU2022219373A1 (en) 2021-02-15 2023-08-24 Takeda Pharmaceutical Company Limited Cell therapy compositions and methods for modulating tgf-b signaling
US11931420B2 (en) 2021-04-30 2024-03-19 Celgene Corporation Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
AU2022304582A1 (en) 2021-06-29 2024-02-01 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
WO2023033129A1 (ja) 2021-09-03 2023-03-09 東レ株式会社 癌の治療及び／又は予防用医薬組成物
WO2023031445A2 (en) 2021-09-06 2023-03-09 Veraxa Biotech Gmbh Novel aminoacyl-trna synthetase variants for genetic code expansion in eukaryotes
CA3238627A1 (en) 2021-11-25 2023-06-01 Christine Kohler Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion
EP4186529A1 (de) 2021-11-25 2023-05-31 Veraxa Biotech GmbH Verbesserte antikörper-nutzlast-konjugate (aps), hergestellt durch ortsspezifische konjugation mittels genetischer codeerweiterung
WO2023104941A1 (en) 2021-12-08 2023-06-15 European Molecular Biology Laboratory Hydrophilic tetrazine-functionalized payloads for preparation of targeting conjugates
EP4372000A2 (de) 2022-02-15 2024-05-22 Tagworks Pharmaceuticals B.V. Maskiertes il12-protein
US20230338424A1 (en) 2022-03-02 2023-10-26 Lentigen Technology, Inc. Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
US11590169B1 (en) 2022-03-02 2023-02-28 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD123 immunotherapy
US20240058465A1 (en) 2022-06-30 2024-02-22 Sutro Biopharma, Inc. Anti-ror1 antibody conjugates, compositions comprising anti ror1 antibody conjugates, and methods of making and using anti-ror1 antibody conjugates
WO2024013723A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof
WO2024026107A2 (en) 2022-07-28 2024-02-01 Lentigen Technology, Inc. Chimeric antigen receptor therapies for treating solid tumors
US20240075142A1 (en) 2022-08-26 2024-03-07 Lentigen Technology, Inc. Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy
WO2024080872A1 (en) 2022-10-12 2024-04-18 Tagworks Pharmaceuticals B.V. Strained bicyclononenes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
GB8821785D0 (en) * 1988-09-16 1988-10-19 Nycomed As Peptide compounds

Also Published As

Publication number Publication date
JP3579751B2 (ja) 2004-10-20
PT695758E (pt) 2002-09-30
ATE217883T1 (de) 2002-06-15
EP0695758A3 (de) 1997-11-26
ES2176285T3 (es) 2002-12-01
EP0695758B1 (de) 2002-05-22
DE69526756T2 (de) 2002-11-07
US5521284A (en) 1996-05-28
DE69526756D1 (de) 2002-06-27
CA2154206A1 (en) 1996-02-02
EP0695758A2 (de) 1996-02-07
JPH0881493A (ja) 1996-03-26

Similar Documents

Publication Publication Date Title
DK0695758T3 (da) Pentapeptidamider og -estere til inhibering af human cancer
BR9808491A (pt) Compostos calcilìticos
DK0973920T3 (da) Et oleosin 5'-regulerende område til modifikationen af plantefrölipidsammensætning
EA200300566A1 (ru) Применение cci-779 в качестве противоопухолевого средства
DK0467792T3 (da) Fungicid komposition til behandling af udsæd
DK0773940T4 (da) Fremgangsmåde til syntese af substituerede sulfoxider
DE69612003T2 (de) Substituierte benzolaktamverbindungen als substanz-p-antagonisten
ATA227794A (de) Beschlag zur höhenverstellung von schubladen
DE69729877D1 (de) Mycophenol bisphosponatverbindungen
DE69509544T2 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
FI940102A0 (fi) Foerfarande och anordning foer hoejande av en materialbanas glans och ytjaemnhet
IT1285770B1 (it) Composti corticoidei
DK145393D0 (da) Proteinmarkoerer til forudsigelse af akut allotransplantatafstoedning
MY106522A (en) Arylaminocarbonyl compounds.
NO981195D0 (no) Nye aminoresin sammensetninger
DK0815092T3 (da) Fremgangsmåde til fremstilling af 1,2-benzisothiazolin-3-oner
DK0915858T3 (da) Mellemprodukter til fremstilling af 2-imidazolin-5-oner
ATE99687T1 (de) Strobilurinderivate, ihre herstellung und verwendung.
FR2707464B1 (fr) Perfectionnement aux articles chaussants.
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
FI945414A0 (fi) Menetelmä N,N-disubstituoidun aminofenolin valmistamiseksi
DK0783491T3 (da) Fremgangsmåde til fremstilling af 3,3,5-trichlorglutarimid
FI934920A0 (fi) Gjutstycke, foerfarande foer dess framstaellning och anvaendning av det
FI942178A0 (fi) Foerfarande foer framstaellning av en lerduva
FI960989A0 (fi) Foerfarande foer virkestorkning